ABC.L Regulatory News (ABC)

2 Apr 2008 07:01

ABCAM Plc02 April 2008 For immediate release 2 April 2008 ABCAM PLC ("Abcam" or "the Company") Director's Dealings Cambridge UK, 2 April 2008: Abcam plc announces that, on 1 April 2008, DavidCleevely, Non-Executive Chairman, sold 600,000 Ordinary Shares of 1p each inthe Company at a price of 345p per share to institutional investors. Followingthe disposal Dr Cleevely has a beneficial interest in 3,569,760 shares,representing 10.19% of the Company's issued share capital. For the purposes of the Financial Services Authority's Disclosure andTransparency Rules, the total number of ordinary shares of 1p of Abcam in issueon the date of admission will be 35,027,479 with each share holding one votingright. The above figure may be used by shareholders as the denominator for thecalculations by which they will determine if they are required to notify theirinterest in, or a change to their interest in, the Company under the Disclosureand Transparency Rules. For further information please contact: Abcam + 44 (0) 1223 696000Jonathan Milner, Chief Executive OfficerJeffrey Iliffe, Chief Financial Officerwww.abcam.com Numis Securities + 44 (0) 20 7260 1000James Black / Nick Westlake Buchanan Communications + 44 (0) 20 7466 5000Mark Court / Mary-Jane Johnson /Susanna Gale Notes for editors: About Abcam plc Abcam is a producer and distributor of research-grade antibodies headquarteredin Cambridge, UK, with a US office located in Cambridge, Massachusetts and aJapanese office in Tokyo. Abcam was admitted to AIM in November 2005 and tradesunder the ticker symbol ABC. The Company produces and distributes its own andthird party produced antibodies to academic and commercial users throughout theworld with product information provided and ordering available through theCompany's website, www.abcam.com. The antibodies are sold under the Abcam brandname. The Company's vision is to build the largest online antibody resource inthe world while also ensuring that the antibodies are of high quality andcommercially viable. Abcam now has an online catalogue of over 42,000 products,most of which are antibodies, from over 200 suppliers supported by up-to-dateand detailed technical data sheets, which are created by the Company. TheCompany currently employs 178 staff in its three operating companies. This information is provided by RNS The company news service from the London Stock Exchange